Key result
Myocardial preconditioning provides profound myocardial protection following sublethal ischaemia, though absolute proof of its existence in humans is still awaited.
Understanding the mechanisms of myocardial preconditioning could lead to the development of novel therapeutic agents to protect infarcting myocardium.
Answers are grounded in this paper and cite their sources.
Should not alter ischaemic heart disease management; leaves open development of preconditioning mimetics pending human confirmation.
SUMMARY Myocardial preconditioning describes the profound myocardial protection that follows a short episode of sublethal ischaemia. Adenosine is produced in ischaemic myocardium and is thought to be an important trigger of the protective mechanism. The exact pathway awaits full elucidation but activation of G proteins and subsequently protein kinase C appear to be important signals. End effectors responsible for delaying cell death include opening of K + ATP ion channels and the transcription of a family of cytoprotective proteins. Absolute proof that preconditioning occurs in man is still awaited, although cross clamping of the aorta during cardiac surgery, balloon inflation during coronary angioplasty, warm‐up angina and preinfarction angina are surrogate models supporting its existence. A clearer understanding of the protective mechanisms involved could lead to the development of novel therapeutic agents that could save the infarcting myocardium.
No takes yet. Share an insight, caveat, or question.
Edwards et al. (1998) conducted a review in Myocardial ischaemia. Myocardial preconditioning was evaluated. Myocardial preconditioning provides profound myocardial protection following sublethal ischaemia, though absolute proof of its existence in humans is still awaited.
Synapse has enriched 10 related papers. Consider them for comparative context: